FDA has approved Alzinova's IND application for a Phase II clinical study with the vaccine candidate ALZ-101 in Alzheimer’s disease.

Les Laboratoires Servier said that it agreed to acquire a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD), from its original developer ...

ApoD may represent a target for therapeutic intervention designed to protect against severe influenza virus infection in elderly populations.

Prior dengue infection reprograms the immune system, boosting vaccine responses. This may shape global strategies for safer, more effective dengue control.

Acetyl-CoA is essential to cell function, and research shows that cancer cells can use different nutrients and different paths to produce it.

The new AI model uses epigenetic data to predict long-term CHO stability and relies on machine learning techniques, such as random forest.

Encouraging development of CGT capacity in Canada, and small markets in general,will require collaboration, Germain says, citing InvestOntario and OmniaBio’s partnership, and the investment arm ...

Optimizing bioprocessing clarification using quality by design affects critical quality attributes and improves product quality.

AI is driving exponential growth in sustainable bioprocessing and automation through computational advances and collaboration.

Ionis Pharmaceuticals' shares surged 42% this past week after the developer of RNA-targeted therapies came out with positive data from two pivotal Phase III trials assessing a potential new indication ...

New research reveals promising drug targets to block coronaviruses at multiple stages of infection—even across different ...

A customizable protein, Crunch, harnesses the body’s natural cleanup system to remove harmful cells, opening new potential ...